Kalaris Therapeutics Inc
KLRS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$37.49M
Close$
$6.33
301.7% upside
Current Fair Value
301.7% upsideUndervalued by 301.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $37.49 Million |
|---|---|
| Enterprise Value | $-8,559,155.00 |
| Earnings per Share | $-2.85 |
| Beta | 0.21 |
| Outstanding Shares | 23,804,981 |
Return
| Return on Equity | -91.55% |
|---|---|
| Return on Assets | -48.76% |
| Return on Invested Capital | -58.18% |
Valuation & Multiples
| P/E Ratio | -0.86 |
|---|---|
| PEG | 11.73 |
| Price to Sales | - |
| Price to Book Ratio | 1.58 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | 0.18 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.16 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 11, 2026
EPS Estimate
-$0.52
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
March 16, 2027
EPS Estimate
-$0.51
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.48%▼ 75.31% |
|---|---|
| Total Invested | $333,451▼ 99.55% |
| Investors Holding | 6▼ 50.00% |
About Kalaris Therapeutics Inc
14 employees
CEO: Mr. Andrew Oxtoby
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.